New research indicates that people who come off new weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass far faster than those who stop conventional diet and exercise plans.
Published data in a leading medical journal shows that while obese individuals can lose substantial amounts of their total mass while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month upon discontinuation.
"Users using these medications must be aware of the danger of quick weight regain when the treatment is stopped," stated lead investigator Dr. Susan Jebb.
Such speed of recovery implies a return to original mass within about a year and a half.
Weighing Therapies
The research, which reviewed dozens of studies involving over 9,000 of patients, compared the outcomes of these new drugs with other pills.
Scientists point out that people who lose weight through lifestyle changes alone usually experience a slower creep back—approximately 0.1 kg a month—post-intervention.
Explaining the Fast Regain
Nutrition scientists propose the mechanism of the injections accounts for the heightened rebound.
The injections imitate a body's own chemical called glucagon-like peptide-1, which controls hunger.
"Long-term administration of the hormone levels far above than normal may cause the body to produce less of its endogenous hormone, and could lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition researcher.
"Stopping of this medication leads to appetite is uncontrolled, making overeating much more probable."
A Lifelong Condition?
Health authorities recommend the jabs for individuals with weight-linked health risks, alongside recommended diet and exercise modifications.
Many experts argue that, given the high risk of weight regain, the therapy is often life-long.
This view is echoed by drug manufacturers, who note that the results "highlight the long-term character of excess weight," comparing it to managing conditions like diabetes.
Patient Testimonies
People who have stopped the jabs report a sudden resurgence of cravings.
"I experienced a switch activating and you're instantly extremely hungry," recalled an individual.
This difficulty is exacerbated if patients have not established lasting dietary or behavioural modifications during treatment.
Significant Adoption
Survey data indicate that a significant number of adults in the UK have used these injections in the past year, with demand continuing to grow.
- Adoption is more common among females compared to men.
- The 40s and 50s demographic shows the highest usage rates.
- Many access the drugs through private prescriptions rather than public health services.
Ultimately, researchers stress that while GLP-1 drugs are potent tools for shedding pounds, they are not a standalone fix and maintained weight loss relies on combined behavioural changes.
